Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market.
“The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” Sandy Macrae, CEO of Sangamo, said in a company news release. “We’re thrilled to work with our colleagues in France toward an exciting new future together developing CAR-Tregs. By combining Sangamo’s zinc finger nuclease gene editing technology with TxCell’s CAR-Treg platform, we have the potential to develop a pipeline of novel cell therapies for patients suffering from autoimmune and inflammatory disorders.”
In 2019, Sangamo expects to submit a clinical trial authorization application (CTA) in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant.
On October 1, 2018, Sangamo acquired a majority stake in TxCell. A simplified cash tender offer was then conducted from November 1, 2018 until November 23, 2018, for the purchase of outstanding ordinary shares of TxCell. Upon completion of the simplified tender offer, on November 23, 2018, Sangamo held 95.71 percent of the share capital and voting rights of TxCell. On November 29, 2018, through a squeeze-out procedure, Sangamo acquired all remaining shares of TxCell.